Marcin Kurzyna: ESC Guidelines on Pregnancy and Cardiovascular Disease Highlight Updates in VTE Treatment
Marcin Kurzyna, Professor of Medicine and Head of the Department of Pulmonary Circulation, Thromboembolic Diseases, and Cardiology at the Centre of Postgraduate Medical Education, shared a post on X:
“European Society of Cardiology Guidelines on cardiovascular disease and pregnancy. Short summary on VTE treatment in pregnancy
Main points:
– in primary prophylaxis, a fixed prophylaxis dose of LMWH is recommended over weight-adjusted dosage protocols
– Pregnancy Heart Team should be involved in pulmonary embolism management
– LMWHs are 1-st line treatment in doses adjusted for early pregnancy body weight
– Catheter-directed therapies or systemic thrombolysis should be recommended in high-risk PE in pregnancy.”
Read the full article here.
Title: 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy
Authors: Julie De Backer, Kristina H Haugaa, Nina Eide Hasselberg, Michèle de Hosson, Margarita Brida, Silvia Castelletti, Matthew Cauldwell, Elisabetta Cerbai, Lia Crotti, Natasja M S de Groot, Mette-Elise Estensen, Eva S Goossens, Bernhard Haring, Donata Kurpas, Carmel M McEniery, Sanne A E Peters, Amina Rakisheva, Antonia Sambola, Oliver Schlager, Florian S Schoenhoff, Tommaso Simoncini, Françoise Steinbach, Isabella Sudano, Lorna Swan, Anne Marie Valente
Stay updated on the latest scientific advancements with Hemostasis Today.
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor
-
Jan 16, 2026, 04:51Higher-Dose Clotting Factor Prophylaxis Does Not Reduce Postpartum Hemorrhage in Women with von Willebrand Disease
-
Jan 16, 2026, 04:48Reza Shojaei on Plasma Donation as Life-Changing Medicine in Motion
-
Jan 16, 2026, 04:11Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
-
Jan 16, 2026, 04:11Why is DVT More Common In the Left Leg? Dr Raheel Moazzam’s New Study Gives Answers!